Redox imbalance

Cell and Tissue Research

Volumn 318, Issue 1, 2004, Pages 201-213

  Berg, Daniela ^a   Youdim, Moussa B H ^b   Riederer, Peter ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

DNA damage; Parkinson's disease; Reactive nitrogen species; Reactive oxygen species; Redox imbalance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIPARKINSON AGENT; ASCORBIC ACID; COPPER; CYANOCOBALAMIN; DNA; DOPAMINE; EXOTOXIN; FLAVONOID; FOLIC ACID; FREE RADICAL; GLUTATHIONE; HEAVY METAL; HYDROXYL RADICAL; IRON; LEVODOPA; MANGANESE; NEUROMELANIN; NITRIC OXIDE; PEROXYNITRITE; PESTICIDE; PYRIDOXINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER; SELENIUM; SUPEROXIDE; UBIDECARENONE;

ANIMAL CELL; ANIMAL MODEL; ASTROCYTE; CELL DEATH; CYTOTOXICITY; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DNA DAMAGE; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GLIA CELL; LEWY BODY; LIPID PEROXIDATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE;

ANIMALIA;

EID: 5444259698     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00441-004-0976-5     Document Type: Review

References (155)

1. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 69:1196-1203
2. Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 32:114-118
3. Antunes F, Han D, Rettori D, Cadenas E (2002) Mitochondrial damage by nitric oxide potentiated by dopmaine in PC12 cells. Biochim Biophys Acta 1556:233-238
4. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S (1987) Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol 45:299-306
5. Beal MF (2003) Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53:S39-S47
6. Beck KD, Knusel B, Hefti F (1993) The nature of the trophic action of brain-derived neurotrophic factor, des(T-3)-insulin-like growth factor, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience 52:855-866
7. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45:182-184
8. Beckmann JS (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9:836-844
9. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991a) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441-1444
10. Ben-Shachar, D, Riederer, P, Youdim, MB (1991b) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem 57:1609-1614
11. Berg D, Grote C, Rausch W-D, Mäurer M, Wesemann W, Riederer P, Becker G (1999a) Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol 25:901-904
12. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Freier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra-association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-1005
13. Bharat S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64:1037-1048
14. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, Hetet G, Brice A, Durr A, Grandchamp B (2002) French Parkinson's disease genetic study group. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 249:801-804
15. Braak H, Del Tredici K, Vos RA de, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
16. Bredt DS (1999) Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 31:577-596
17. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23:655-664
18. Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25:437-444
19. Carreras MC, Franco MC, Peralta JG, Poderoso JJ (2004) Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease. Mol Aspects Med 25:125-139
20. Castellani RJ, Siedlak SL, Perry S, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100:111-114
21. Chan TS, Teng S, Wilson JX, Galati G, Khan S, O'Brien PJ (2002) Coenzyme Q cytoprotective mechanisms for mitochondrial complex I cytopathies involves NAD(P)H: quinone oxidoreductase 1(NQO1). Free Radic Res 36:421-427
22. Choi HJ, Kim SW, Lee SY, Hwang O (2003) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 86:143-152
23. Cuajungco MP, Lees GJ (1997) Zinc metabolism in the brain: relevance to human neurodegenerative disorders. Neurobiol Dis 4:137-169
24. + binds to neuromelanin. Science 231 987-989
25. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52:1-6
26. David GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1:249-PF Sz
27. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822
28. Deplazes J, Schobel K, Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Becker G, Riess O, Berg D (2004) Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. J Neural Transm 111:515-521
29. Desagher S, Glowinski J, Premont J (1997) Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J Neurosci 17:9060-9067
30. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389
31. Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60:273-281
32. Double KL, Riederer P, Gerlach M (1999) Significance of neuromelanin for neurodegeneration in Parkinson's disease. Drug News Perspect 12:333-340
33. Double KL, Gerlach M, Youdim MBH, Riederer P (2000) Impaired iron homeostasis in Parkinson's disease. J Neural Transm 60:37-58
34. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003a) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66:489-494
35. Double KL, Halliday GM, Henderson J, Griffiths FM, Heinemann T, Riederer P, Gerlach M (2003b) The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp Neurol 184:530-535
36. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 86:1142-1148
37. Felletschin B, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Sommer U, Zeiler B, Becker G, Riess O, Berg D (2003) Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett 352:53-56
38. Fiskum G, Starkov A, Polster BM, Chinopoulos C (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann N Y Acad Sci 991:111-119
39. Forsleff L, Schauss AG, Bier ID, Stuart S (1999) Evidence of functional zinc deficiency in Parkinson's disease. J Altern Complement Med 5:57-64
40. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglia activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297
41. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255
42. Gasser T (2003) Molecular genetics of Parkinon's disease, In: Calne D, Calne S (eds) Parksinon's disease. Advances in neurology, vol 86. Lippincott, Philadelphia, pp 23-32
43. Gerber GB, Leonard A, Hantson P (2002) Carcinogenicity, mutagenicity and teratogenicity of manganese compounds. Crit Rev Oncol Hematol 42:25-34
44. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 63:793-807
45. Gerlach M, Riederer P, Youdim MBH (1996) Molecular mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and exitotoxic amino acids, In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Parkinson's disease. Advances in neurology, vol 69. Lippincott, Philadelphia, pp 177-194
46. Gerlach M, Reichmann H, Riederer P (2001) Die Parkinsonkrankheit, Grundlagen, Klinik, Therapie. Springer, Berlin Heidelberg New York
47. Giasson BI, Duda JE, Murray ChenQ IV, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 3:985-989
48. Goetz ME, Gerlach M (2004) Formation of radicals. In: Herdegen T, Delgado-Garcia J (eds) Brain damage and repair. Kluwer, London, pp 135-164
49. Golbe LI, Mouradian MM (2004) Alpha-synuclein in Parkinson's disease: light from two new angles. Ann Neurol 55:153-156
50. Golts N, Snyder H, Frasier M, Theisler C, Choi P, Wolozin B (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J Biol Chem 277:16116-16123
51. Good P, Olanow C, Perl D (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study. Brain 593:343-346
52. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress. Free radical production in neural degeneration. Pharmacol Ther 63:37-122
53. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ (1999) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20:239-247
54. Graumann R, Paris I, Martinez-Alvarado P, Rumanque P, Perez-Pastene C, Cardenas SP, Marin P, Diaz-Grez F, Caviedes R, Caviedes P, Segura-Aguilar J (2002) Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol J Pharmacol 54:573-579
55. Grisham MB, Jourd'Heul D, Wink DA (1999) Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am J Physiol 276:315-321
56. Gu M, Cooper JM, Taanman JW, Schapira AHV (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44:177-186
57. Gu G, Reyes PE, Golden GT, Woltjer RL, Hulette C, Montine TJ, Zhang J (2002) Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. J Neuropathol Exp Neurol 61:634-639
58. Hallgren B, Sourander P (1958) The effect of age on non-haem iron in the human brain. J Neurochem 3:41-51
59. Halliwell B, Gutteridge JM (2003) Free radicals in biology and medicine. Oxford University, New York
60. HaMai D, Bondy SC (2004) Oxidative basis of manganese neurotoxicity. Ann N Y Acad Sci 1012:129-141
61. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M, Masliah E (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799:301-306
62. He Y, Thong PS, Lee T, Leong SK, Shi CY, Wong PT, Yuan SY, Watt F (1996) Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res 735:149-153
63. Hirsch EC, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348
64. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, Zeiler B, Bornemann A, Pahnke J, Becker G, Riess O, Berg D (2004) Ceruloplasmin gene variations are associated with substantia nigra hyperechogenicity in Parkinson's disease. Neurology (in press)
65. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86:1297-1307
66. Hunot S, Dugas N, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC (1999) Fcepsilon-RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19:3440-3447
67. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110:49-58
68. Jahngen-Hodge J, Obin MS, Gong X, Shang F, Nowell TR Jr, Gong J, Abasi H, Blumberg J, Taylor A (1997) Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 272:28218-28226
69. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachellberger H, Ben-Shachar D, Youdim MB (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 59:1168-1171
70. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146:6-13
71. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53:S26-S38
72. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson's disease. Ann Neurol 44:S72-S84
73. Jimenez-Jimenez FJ, Molina JA, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, Bustos F de, Martinez-Salio A, Orti-Pareja M, Zurdo M, Martinez-Para MC (1998) Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm 105:497-505
74. Junn E, Mouradian MM (2002) Human alpha-synuclein overexpression increases intracellular reactive oxygen species and suceptibility to dopamine. Neurosci Lett 320:146-150
75. Kanthasamy AG, Kitazawa M, Kaul S, Yang Y, Lahiri DK, Anantharam V, Kanthasamy A (2003) Proteolytic activation of proapoptotic kinase PKCdelta is regulated by overexpression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson's disease. Ann N Y Acad Sci 1010:683-686
76. Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, Kim HK, Yang SO, Chung HK, Lee DS, Jeon B (2002) Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 17:568-575
77. Kish SJ, Morito CH, Hornykiewics (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neruosci Lett 58:343-346
78. + analogs acting on mitochondria and inducing neuro-degeneration. Curr Med Chem 10:2507-2516
79. Koutsilieri E, Scheller C, Tribl F, Riederer P (2002) Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism Relat Disord 8:401-406
80. Kramer BC, Yabut JA, Cheong J, JnoBaptiste R, Robakis T, Olanow CW, Mytilineou C (2002) Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanism of protection. Neuroscience 114:361-372
81. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF (2003) Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease α-synuclein fibrillogenesis. Biochemistry 42:829-837
82. Lan J, Jiang DH (1997) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104:649-660
83. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:989-990
84. 2. J Neurochem 84:1128-1142
85. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132
86. Liu B, Gao H, Wang J, Jeohn G, Cooper C, Hong J (2002a) Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 962:318-331
87. Liu Y, Fiskum G, Schubert D (2002b) Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 80:780-787
88. Lopiano L, Chiesa M, Digilio G, Giraudo S, Bergamasco B, Torre E, Fasano M (2000) Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim Biophys 17:306-312
89. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S (2004) Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 44:355-360
90. Mandel S, Weinreb O, Amit T, Youdim MB (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: implications for neurodegenerative diseases. J Neurochem 88:1555-1569
91. Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21:361-370
92. Manilla RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide-dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86:321-331
93. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269
94. Mattson MP (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 1012:37-50
95. McNaught KSP, Jenner P (2000) Extracellular accumulation of nitric oxide, hydrogen peroxide and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition and/or lipopolysaccharide-induced activation. Biochem Pharmacol 60:979-988
96. Mendez-Alvarez E, Soto-Otero R, Hermida-Ameijeiras A, Lopez-Real AM, Labandeira-Garcia JL (2002) Effects of aluminum and zinc on the oxidative stress caused by 6-hydroxydopamine autoxidation: relevance for the pathogenesis of Parkinson's disease. Biochim Biophys Acta 1586:155-168
97. Minghetti L, Levi G (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog Neurobiol 54:99-125
98. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455
99. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 168:251-253
100. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150
101. Münch G, Lüth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of α-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation. J Clin Neuroanat 20:253-257
102. Mytilineou C, Kramer BC, Yabut JA (2002) Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 8:385-38
103. Naoi M, Maruyama W, Akao Y, Zhang J, Parvez H (2000) Apoptosis induced by an endogenous neurotoxin, N-methyl(R) salsolinol, in dopamine neurons. Toxicology 153:123-141
104. Naoi M, Maruyama W, Akao Y, Yi H (2002) Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm 109:607-621
105. Paik, S, Shin, H, Lee, J, Chang, C, Kim, J (1999) Copper(II)-induced self oligomerization of α-synuclein. Biochem J 340:821-828
106. Paris I, Dagnino-Subiabre A, Marcelain K, Bennett LB, Caviedes P, Caviedes R, Azar CO, Segura-Aguilar J (2001) Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J Neurochem 77:519-529
107. Plaitakis A, Shashidharan P (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 247:825-835
108. Power JH, Shannon JM, Blumbergs PC, Gai WP (2002) Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson's disease and dementia with lewy bodies. Am J Pathol 161:885-894
109. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2003) Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60:1761-1766
110. Practice D (2001) In vivo measurement of the redox state. Lipids 36: S45-S49
111. Rajput AH, Uitti RJ, Stern W, Laverty W (1986) Early onset Parkinson's disease and childhood environment. Adv Neurol 45:295-297
112. Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50:202-208
113. Reichmann H, Janetzky B (2000) Mitochondrial dysfunction-a pathogenetic factor in Parkinson's disease. J Neurol 247:863-867
114. Reichmann H, Riederer P (1989) Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson's disease. BMFT Symposium "Morbus Parkinson und andere Basalganglienerkrankungen", Bad Kissingen (Abstract S 44)
115. Reif DW, Simmons RD (1990) Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283:537-541
116. Riederer P, Youdim MBH (eds) (1993) Iron in central nervous system disorders. Springer, Vienna
117. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson's disease. M Sinai J Med 55:21-28
118. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515-520
119. Rossi L, Lombardo MF, Ciriolo MR, Rotilio G (2004) Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res 29:493-504
120. Sanchez-Ramos JR, Hefti F, Weiner WJ (1987) Paraquat and Parkinson's disease. Neurology 37:728b
121. Sanchez-Ramos JR, Övervik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204
122. Scherman D, Desnos C, Darchen F, Javoy-Agid F, Agid Y (1989) Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26:551-557
123. Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 150:60-68
124. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46:254-263
125. Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T (2003) An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74:589-597
126. Shaw CA, Bains JS (2002) Synergistic versus antagonistic actions of glutamate and glutathione: the role of excitotoxicity and oxidative stress in neuronal disease. Cell Mol Biol 48:127-136
127. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M (2002a) An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015
128. Sherer TB, Betarbet R, Greenamyre JT (2002b) Environment, mitochondria, and Parkinson's disease. Neuroscientist 8:192-197
129. Shima T, Sarna T, Swartz H, Stroppolo A, Gerbasi R, Zecca L (1997) Binding of iron to neuromelanin of human substantia nigra and synthetic neuromelanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 23:110-119
130. Shoham S, Youdim MB (2002) The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin. J Neural Transm 109:1241-1256
131. Shoulson I (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 44:S160-S166
132. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36:356-361
133. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74:199-205
134. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130
135. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344-18349
136. Spencer PS, Nunn PB, Hugon J, Ludolph AC, Ross SM, Roy DN, Robertson RC (1987) Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 237:517-522
137. Stadtman ER (2001) Protein oxidation in aging and age-related diseases. Ann N Y Acad Sci 928:22-38
138. Starkov AA, Polster BM, Fiskum G (2002) Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax. J Neurochem 83:220-228
139. Stewart VC, Heales SJR (2003) Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic Biol Med 34:287-303
140. Strijks E, Kremer HP, Horstink MW (1997) Q10 therapy in patients with idiopathic Parkinson's disease. Mol Aspects Med 18 (Suppl):S237-S240
141. Tanaka M (2002) Mitochondrial genotypes and cytochrome b variants associated with longevity or Parkinson's disease. J Neurol 249:III1-III8
142. Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP Jr, Miller SW, Davis RE, Parker WD Jr (2000) Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 162:37-50
143. Turnbull S, Tabner BJ, El-Agnaf OMA, Moore S, Davies Y, Allsop D (2001) α-Synuclein implicated in Parkinons's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30:1163-1170
144. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 276:44284-44296
145. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND (2004) Glutathione metabolism and its implications for health. J Nutr 134:489-492
146. Yoshida E, Mokuno K, Aoki SI, Takahashi A, Riku S, Murayama T, Yanagi T, Kato K (1994) Cerebrospinal fluid levels of superoxide dismutase. J Neurol Sci 124:25-31
147. Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325
148. Zafar KS, Siddiqui A, Sayeed I, Ahmad M, Salim S, Islam F (2003) Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences. J Neurochem 84:438-446
149. Zareba M, Bober A, Korytowski W, Zecca L, Sarna T (1995) The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta 1271:343-348
150. Zecca L, Swartz HM (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm 5:203-213
151. Zecca L, Mecacci O, Seraglia R, Parati E (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1138:6-10
152. Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin in substantia nigra of normal subjects at different ages, consequences for iron storage and neurodegenerative processes. J Neuochem 76:1766-1773
153. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral dopamine, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkisnon's disease. FEBS Lett 510:216-220
154. Zhang J, Fitsanakis VA, Gu G, Jing D, Ao M, Amarnath V, Montine TJ (2003) Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem 84:336-346
155. Zhu BT (2004) CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. Int J Mol Med 13:343-353